RHHBY - Roche teams up with Blueprint Medicines in RET-altered cancers July, 14 2020 07:02 AM Roche Holding Ltd ADR Building on their 2016 partnership aimed at developing up to five kinase inhibitors in cancer, Roche (OTCQX:RHHBY) and Blueprint Medicines (NASDAQ:BPMC) ink a new license and collaboration agreement to develop and commercialize RET inhibitor pralsetinib.More news on: Roche Holding AG, Blueprint Medicines Corporation, CSTONE PHARMACEUTICALS, Healthcare stocks news, Stocks on the move, Read more ...